Novavax has finalized agreements with major pharmacy retailers and prominent Group Purchasing Organizations in the United States to provide the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) to prevent COVID-19 in individuals aged 12 and older this vaccination season.
Through these agreements Novavax's updated COVID-19 vaccine will be widely available across the United States, including but not limited to, Costco, CVS Pharmacy, Giant, Publix, Rite Aid, Stop & Shop and Topco, a large retail purchaser for member pharmacies. Novavax's vaccine received Emergency Use Authorization from the Food and Drug Administration on Oct. 3, 2023.
"We are committed to ensuring immediate nationwide availability of our protein-based non-mRNA vaccine, and our agreements with leading U.S. pharmacy retailers will ensure people have options to help protect themselves and their loved ones against COVID-19 this fall," said John Jacobs, president and CEO of Novavax. "Individuals will have access to our protein-based vaccine through major pharmacies, clinics, physicians' offices and government programs."
[Read more: Rite Aid to hold Family Immunization Day]
In addition to retail pharmacies, physicians' offices and public health clinics, Novavax's vaccine will be available through various government entities such as Vaccines for Children, Federal Qualified Health Centers, Indian Health Services and the U.S. Department of Defense. In addition, Novavax has donated product to "Bridge Access Program For COVID Vaccines and Treatments" to provide access for adults in the U.S. without other sources of coverage.
Novavax said it continues to work with additional retailers and anticipates that the network of partners providing its updated COVID-19 vaccine will continue to grow. The company also will ensure its vaccine is available through GPO agreements, including Vizient, Premier and Healthtrust Purchasing Group, which provide broad access to the U.S. health system landscape.